Glenmark Pharmaceuticals became the first company in India to have begun the phase 3 of clinical trials of antiviral Favipiravir, a potential drug for COVID-19 patients.
“Clinical trials have commenced and over 10 leading government and private hospitals in India are being enrolled for the study. Glenmark estimates study completion by July or August,” the company said in a statement on Tuesday (12 May), News18 reported.
Glenmark was the first company to have received the approval from the Drug Controller General of India late last month, according to news agency ANI.
Favipiravir, as per the report, happens to be a generic version of Avigan of Fujifilm Toyama Chemical Co Ltd in Japan, a subsidiary of Fujifilm Corporation.
The Indian pharma major has developed the active pharma ingredient (API) and the formulations for the product through its R&D team. The drug has acted strongly against influenza (common flu) virus and it has been approved for treatment of novel coronavirus infections in Japan.
if commercialised, the molecule will be sold under the brand name of FabiFlu in India, said the company.
“Several health and medical experts both in and outside of Glenmark are eager to see the effect that Favipiravir has on Covid-19 cases,” Monika Tandon, Vice President and Head of Clinical Development, Global Specialty/Branded Portfolio at Glenmark Pharmaceuticals was quoted as saying by ANI.
“We believe the study results will be significant as there is currently no effective treatment for the virus. The data we get from these trials will point us in a clearer direction with regard to Covid-19 treatment and management,” she said.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 999/year is the best way you can support our efforts.